葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市

智通財經

04/17

智通財經APP獲悉，4月17日，國家藥監局(NMPA)網站顯示，葛蘭素史克(GSK.US)的Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市。根據此前的優先審評信息，此次獲批的適應症為聯合硼替佐米和地塞米松治療既往接受過至少一種治療的多發性骨髓瘤成人患者。

瑪貝蘭妥單抗是Seagen(已被輝瑞收購)開發的一款BCMA ADC。2009年12月，GSK與Seagen達成協議，獲得該藥物的研究、開發、生產和商業化權益。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2628064279"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2628064279\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2628064279?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-17 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628064279","market":"hk","top_or_hot":-1,"title":"葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，4月17日，國家藥監局(NMPA)網站顯示，<a href=\"https://laohu8.com/S/GSK\">葛蘭素史克</a>(GSK.US)的Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市。根據此前的優先審評信息，此次獲批的適應症為聯合硼替佐米和地塞米松治療既往接受過至少一種治療的多發性骨髓瘤成人患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20260417/1776415204342722.png?x-oss-process=image/format,jpg/quality,q_90\" title=\"1776415204342722.png\"/></p><p>瑪貝蘭妥單抗是<a href=\"https://laohu8.com/S/SGEN\">Seagen</a>(已被<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>收購)開發的一款BCMA ADC。2009年12月，GSK與Seagen達成協議，獲得該藥物的研究、開發、生產和商業化權益。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-04-17 16:39</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，4月17日，國家藥監局(NMPA)網站顯示，<a href=\"https://laohu8.com/S/GSK\">葛蘭素史克</a>(GSK.US)的Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市。根據此前的優先審評信息，此次獲批的適應症為聯合硼替佐米和地塞米松治療既往接受過至少一種治療的多發性骨髓瘤成人患者。</p><p><img src=\"https://img.zhitongcaijing.com/image/20260417/1776415204342722.png?x-oss-process=image/format,jpg/quality,q_90\" title=\"1776415204342722.png\"/></p><p>瑪貝蘭妥單抗是<a href=\"https://laohu8.com/S/SGEN\">Seagen</a>(已被<a href=\"https://laohu8.com/S/PFE\">輝瑞</a>收購)開發的一款BCMA ADC。2009年12月，GSK與Seagen達成協議，獲得該藥物的研究、開發、生產和商業化權益。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1429939.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSKH","symbol_name":"GSK plc ADRhedged","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1429939.html","article_id":"2628064279","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628064279","pubTimestamp":1776415186,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，4月17日，國家藥監局(NMPA)網站顯示，葛蘭素史克(GSK.US)的Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市。根據此前的優先審評信息，此次獲批的適應症為聯合硼替佐米和地塞米松治療既往接受過至少一種治療的多發性骨髓瘤成人患者。瑪貝蘭妥單抗是Seagen(已被輝瑞收購)開發的一款BCMA ADC。2009年12月，GSK與Seagen達成協議，獲得該藥物的研究、開發、生產和商業化權益。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GSKH":"GSK plc ADRhedged","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IPOS":"Renaissance International IPO ETF","BK4588":"碎股","BK4532":"文艺复兴科技持仓","BK4007":"制药","GSK":"葛兰素史克","GSK.UK":"葛兰素史克"},"translate_title":"GlaxoSmithKline (GSK.US) Belantamab mafodotin (Mabelantumab) approved for marketing in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK":1.5,"GSK.UK":0.6,"IPOS":1.5},"content_text":"智通財經APP獲悉，4月17日，國家藥監局(NMPA)網站顯示，葛蘭素史克(GSK.US)的Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市。根據此前的優先審評信息，此次獲批的適應症為聯合硼替佐米和地塞米松治療既往接受過至少一種治療的多發性骨髓瘤成人患者。瑪貝蘭妥單抗是Seagen(已被輝瑞收購)開發的一款BCMA ADC。2009年12月，GSK與Seagen達成協議，獲得該藥物的研究、開發、生產和商業化權益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}